Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958–67.
Article
CAS
PubMed
Google Scholar
Isaka T, Yokose T, Ito H, Nagata M, Furumoto H, Nishii T, et al. Correlations between the EGFR mutation status and Clinicopathological features of clinical stage I lung adenocarcinoma. Medicine (Baltimore). 2015;94(42):e1784.
Article
CAS
Google Scholar
Weinstein IB. Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science. 2002;297(5578):63–4.
Article
CAS
PubMed
Google Scholar
Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with Osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):41–50.
Article
CAS
PubMed
Google Scholar
Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213–22.
Article
CAS
PubMed
Google Scholar
Hosomi Y, Morita S, Sugawara S, Kato T, Fukuhara T, Gemma A, et al. Gefitinib alone versus Gefitinib plus chemotherapy for non-small-cell lung Cancer with mutated epidermal growth factor receptor: NEJ009 study. J Clin Oncol. 2020;38(2):115–23.
Article
CAS
PubMed
Google Scholar
Kerr KM, Nicolson MC. Prognostic factors in resected lung carcinomas. EJC Suppl. 2013;11(2):137–49.
Article
PubMed
PubMed Central
Google Scholar
Isaka T, Ito H, Nakayama H, Yokose T, Yamada K, Masuda M. Effect of epidermal growth factor receptor mutation on early-stage non-small cell lung cancer according to the 8th TNM classification. Lung Cancer. 2020;145:111–8.
Article
PubMed
Google Scholar
Isaka T, Ito H, Nakayama H, Yokose T, Saito H, Adachi H, et al. Effect of epidermal growth factor receptor gene mutation on the prognosis of pathological stage II-IIIA (8th edition TNM classification) primary lung cancer after curative surgery. Lung Cancer. 2021;162:128–34.
Article
CAS
PubMed
Google Scholar
Tada H, Mitsudomi T, Misumi T, Sugio K, Tsuboi M, Okamoto I, et al. Randomized phase III study of Gefitinib versus cisplatin plus Vinorelbine for patients with resected stage II-IIIA non-small-cell lung Cancer with EGFR mutation (IMPACT). J Clin Oncol. 2022;40(3):231–41.
Article
CAS
PubMed
Google Scholar
Kelly K, Altorki NK, Eberhardt WE, O'Brien ME, Spigel DR, Crinò L, et al. Adjuvant Erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung Cancer (RADIANT): a randomized, double-blind, phase III trial. J Clin Oncol. 2015;33(34):4007–14.
Article
CAS
PubMed
Google Scholar
Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018;19(1):139–48.
Article
CAS
PubMed
Google Scholar
Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Wei YC, et al. Gefitinib versus Vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 phase III trial. J Clin Oncol. 2021;39(7):713–22.
Article
CAS
PubMed
Google Scholar
Wu YL, Tsuboi M, He J, John T, Grohe C, Majem M, et al. Osimertinib in resected EGFR-mutated non-small-cell lung Cancer. N Engl J Med. 2020;383(18):1711–23.
Article
CAS
PubMed
Google Scholar
D'Antonio C, Passaro A, Gori B, Del Signore E, Migliorino MR, Ricciardi S, et al. Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. Ther Adv Med Oncol. 2014;6(3):101–14.
Article
CAS
PubMed
PubMed Central
Google Scholar
Isaka T, Ito H, Nakayama H, Yokose T, Saito H, Masuda M. Impact of the initial site of recurrence on prognosis after curative surgery for primary lung cancer. Eur J Cardiothorac Surg. 2022;61(4):778–86.
Article
PubMed
Google Scholar
Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, et al. The IASLC lung Cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung Cancer. J Thorac Oncol. 2016;11(1):39–51.
Article
PubMed
Google Scholar
Malapelle U, Sirera R, Jantus-Lewintre E, Reclusa P, Calabuig-Fariñas S, Blasco A, et al. Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer. Expert Rev Mol Diagn. 2017;17(3):209–15.
Article
CAS
PubMed
Google Scholar
Lopez-Rios F, Angulo B, Gomez B, Mair D, Martinez R, Conde E, et al. Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer. J Clin Pathol. 2013;66(5):381–5.
Article
CAS
PubMed
Google Scholar
Yoshida K, Yatabe Y, Park JY, et al. Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. J Thorac Oncol. 2007;2:22–8.
Article
PubMed
Google Scholar
Matsukuma S, Yoshihara M, Kasai F, et al. Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loophybrid mobility shift assay. J Mol Diagn. 2006;8:504–12.
Article
CAS
PubMed
PubMed Central
Google Scholar
Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO classification of Tumours of the lung, pleura, Thymus and heart. Lyon: International Agency for Research on Cancer; 2015.
Google Scholar
Yoshizawa A, Sumiyoshi S, Sonobe M, Kobayashi M, Fujimoto M, Kawakami F, et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol. 2013;8(1):52–61.
Article
CAS
PubMed
Google Scholar
Isaka T, Nakayama H, Ito H, Yokose T, Yamada K, Masuda M. Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery. BMC Cancer. 2018;18(1):959.
Ni J, Guo T, Li Y, Yang X, Li Y, Zou L, et al. Patterns and risks of postoperative recurrence in completely resected EGFR-mutant non-small cell lung cancer: prognostic significance of routine immunohistochemical markers. Transl Lung Cancer Res. 2019;8(6):967–78.
Article
CAS
PubMed
PubMed Central
Google Scholar
Saw SPL, Zhou S, Chen J, Lai G, Ang MK, Chua K, et al. Association of Clinicopathologic and Molecular Tumor Features with Recurrence in resected early-stage epidermal growth factor receptor-positive non-small cell lung Cancer. JAMA Netw Open. 2021;4(11):e2131892.
Article
PubMed
PubMed Central
Google Scholar
Park C, Lee IJ, Jang SH, Lee JW. Factors affecting tumor recurrence after curative surgery for NSCLC: impacts of lymphovascular invasion on early tumor recurrence. J Thorac Dis. 2014;6(10):1420–8.
PubMed
PubMed Central
Google Scholar
Higgins KA, Chino JP, Ready N, et al. Lymphovascular invasion in non-small-cell lung cancer: implications for staging and adjuvant therapy. J Thorac Oncol. 2012;7:1141–7.
Article
PubMed
Google Scholar
Shiono S, Kanauchi N, Yanagawa N, et al. Stage II-IV lung cancer cases with lymphovascular invasion relapse within 2 years after surgery. Gen Thorac Cardiovasc Surg. 2014;62:112–8.
Article
PubMed
Google Scholar
Harada M, Hato T, Horio H. Intratumoral lymphatic vessel involvement is an invasive indicator of completely resected pathologic stage I non-small cell lung cancer. J Thorac Oncol. 2011;6(1):48–54.
Article
PubMed
Google Scholar
Wang J, Chen J, Chen X, Wang B, Li K, Bi J. Blood vessel invasion as a strong independent prognostic indicator in non-small cell lung cancer: a systematic review and meta-analysis. PLoS One. 2011;6(12):e28844.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wang S, Xu J, Wang R, Qian F, Yang W, Qiao R, et al. Adjuvant chemotherapy may improve prognosis after resection of stage I lung cancer with lymphovascular invasion. J Thorac Cardiovasc Surg. 2018;156(5):2006–2015.e2.
Article
PubMed
Google Scholar
Kato T, Ishikawa K, Aragaki M, Sato M, Okamoto K, Ishibashi T, et al. Angiolymphatic invasion exerts a strong impact on surgical outcomes for stage I lung adenocarcinoma, but not non-adenocarcinoma. Lung Cancer. 2012;77(2):394–400.
Article
PubMed
Google Scholar
Mimae T, Tsutani Y, Miyata Y, Yoshiya T, Ibuki Y, Kushitani K, et al. Role of lymphatic invasion in the prognosis of patients with clinical node-negative and pathologic node-positive lung adenocarcinoma. J Thorac Cardiovasc Surg. 2014;147(6):1820–6.
Article
PubMed
Google Scholar
Minder P, Zajac E, Quigley JP, Deryugina EI. EGFR regulates the development and microarchitecture of intratumoral angiogenic vasculature capable of sustaining cancer cell intravasation. Neoplasia. 2015;17(8):634–49.
Article
CAS
PubMed
PubMed Central
Google Scholar
De Luca A, Gallo M, Aldinucci D, Ribatti D, Lamura L, D’Alessio A, et al. Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells. J Cell Physiol. 2011;226(8):2131–8.
Article
PubMed
CAS
Google Scholar
Lin TY, Yang CH, Chou HC, Cheng CM, Liu YW, Wang JY, et al. EGFR mutation-harboring lung Cancer cells produce CLEC11A with endothelial trophic and tumor-promoting activities. Cancers (Basel). 2022;14(5):1356.
Article
CAS
Google Scholar
Tseng CH, Chiang CJ, Tseng JS, Yang TY, Hsu KH, Chen KC, et al. EGFR mutation, smoking, and gender in advanced lung adenocarcinoma. Oncotarget. 2017;8(58):98384–93.
Article
PubMed
PubMed Central
Google Scholar
Hasegawa Y, Ando M, Maemondo M, Yamamoto S, Isa S, Saka H, et al. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials. Oncologist. 2015;20(3):307–15.
Article
CAS
PubMed
PubMed Central
Google Scholar
Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012;150(6):1107–20.
Article
CAS
PubMed
PubMed Central
Google Scholar
Govindan R, Ding L, Griffith M, Subramanian J, Dees ND, Kanchi KL, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 2012;150(6):1121–34.
Article
CAS
PubMed
PubMed Central
Google Scholar
Suárez-Piñera M, Belda-Sanchis J, Taus A, Sánchez-Font A, Mestre-Fusco A, Jiménez M, et al. FDG PET-CT SUVmax and IASLC/ATS/ERS histologic classification: a new profile of lung adenocarcinoma with prognostic value. Am J Nucl Med Mol Imaging. 2018;8(2):100–9.
PubMed
PubMed Central
Google Scholar
Tsutani Y, Ito M, Shimada Y, Ito H, Ikeda N, Nakayama H, et al. The impact of epidermal growth factor receptor mutation status on adjuvant chemotherapy for patients with high-risk stage I lung adenocarcinoma. J Thorac Cardiovasc Surg. 2022;S0022-5223(22):00097–6.
Google Scholar
Isaka T, Ito H, Nakayama H, Yokose T, Katayama K, Yamada K, et al. Efficacy of platinum-based adjuvant chemotherapy on prognosis of pathological stage II/III lung adenocarcinoma based on EGFR mutation status: a propensity score matching analysis. Mol Diagn Ther. 2019;23(5):657–65.